WALTHAM, Mass., Sept. 1, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it will present at Baird's 2011 Health Care Conference on Thursday, September 8, 2011, at 12:45 p.m. Eastern Time. Pieter Muntendam, MD, President and CEO of the Company, will participate in a corporate presentation that will include highlights of galectin-3 studies recently presented at the European Society of Cardiology (ESC) Congress 2011. The presentation will be available to the public through a webcast accessible by visiting: http://www.wsw.com/webcast/baird24/bgmd/ or the "Investors" section of the Company's website at www.bg-medicine.com. Replays will be available for 30 days after the presentation.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs. The Company recently launched the BGM Galectin-3TM test for use in patients with heart failure, the first novel blood test for cardiac disease cleared by the U.S. F.D.A. in five years. BG Medicine also has products in development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352
CONTACT: Michael W. Rogers EVP & Chief Financial Officer (781) 890-1199
No comments:
Post a Comment